Secukinumab gives early, sustained enthesitis resolution in PsA
Patients with psoriatic arthritis treated with secukinumab demonstrated early and sustained resolution of enthesitis, with 300 mg doses providing higher resolution than 150 mg in more severe cases, according to data published in Arthritis Research & Therapy.“This study provides more granular detail on responses specifically for enthesitis, which is typically only a secondary endpoint in